A qualitative analysis of prescribers' and dispensers' views on improving prescription drug monitoring programs

被引:12
|
作者
Carnes, Neal A. [1 ,2 ,3 ]
Wright, Eric R. [1 ,2 ,3 ]
Norwood, Connor W. [1 ,2 ,4 ]
机构
[1] Indiana Univ Indianapolis, Richard M Fairbanks Sch Publ Hlth, 714 N Senate Ave, Indianapolis, IN 46202 USA
[2] Indiana Univ Purdue Univ, Ctr Hlth Policy, 714 N Senate Ave, Indianapolis, IN 46202 USA
[3] Georgia State Univ, Dept Sociol, 33 Peachtree Ctr Ave SE,Langdale Hall Suite 1061, Atlanta, GA 30303 USA
[4] Indiana Univ Sch Med, Dept Family Med, Hlth Workforce Studies, 1110 W Michigan St,Long Hall 200, Indianapolis, IN 46202 USA
来源
关键词
Prescription drug monitoring programs; Prescribers; Dispensers; Health policy; Ethics; UNITED-STATES; NONMEDICAL USE; DEATH RATES; ABUSE; OPIOIDS; OVERDOSE;
D O I
10.1016/j.sapharm.2016.12.002
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Prescription drug abuse is epidemic in the United States (US). To help address the problem, most states operate prescription drug monitoring programs (PDMPs). PDMPs are designed to monitor and help control the distribution of controlled therapeutic medications and to assist prescribers and dispensers in making informed clinical decisions. To this end, PDMPs rely on timely and accurate data submission, as well as review of the data. Consequently, provider acceptance of these systems is essential to maximize their effectiveness. Objectives: This article explores licensed prescribers' and dispensers' opinions regarding prescription drug monitoring. Methods: The study surveyed licensed prescribers and dispensers about their experiences and views on drug monitoring, prescribing and dispensing practices, and on prescription drug abuse in general. Two open-ended questions were posed as part of a larger, end-user survey. The analysis culled thematically-coded excerpts to these two questions. Results: Respondents offered a range of comments that unearthed important disagreements among prescribers and dispensers over the administration and ethics pertaining to PDMPs. At the same time, some respondents suggested means to enhance PDMPs functionality. Conclusion: Attending to and rectifying providers' views, while considering their improvement suggestions may boost PDMPs effectiveness by maximizing buy-in and utilization. The potential speaks to advancing a tool that intends to help address alarming rates of prescription drug abuse. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:1167 / 1174
页数:8
相关论文
共 50 条
  • [1] Detecting Anomalous Networks of Opioid Prescribers and Dispensers in Prescription Drug Data
    Rosman, Katie
    Neill, Daniel B.
    THIRTY-SEVENTH AAAI CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOL 37 NO 12, 2023, : 14470 - 14477
  • [2] Concern about the Expanding Prescription Drug Epidemic: A Survey of Licensed Prescribers and Dispensers
    Wright, Eric R.
    Reed, Nia
    Carnes, Neal
    Kooreman, Harold E.
    PAIN PHYSICIAN, 2016, 19 (01) : E197 - E208
  • [3] How Clinicians Use Prescription Drug Monitoring Programs: A Qualitative Inquiry
    Hildebran, Christi
    Cohen, Deborah J.
    Irvine, Jessica M.
    Foley, Carol
    O'Kane, Nicole
    Beran, Todd
    Deyo, Richard A.
    PAIN MEDICINE, 2014, 15 (07) : 1179 - 1186
  • [4] Prescription drug monitoring programs
    Miller, Michael M.
    Brown, Randall T.
    AMERICAN FAMILY PHYSICIAN, 2007, 75 (06) : 810 - 811
  • [5] Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline
    Haines, Sarah
    Lam, Ashley
    Savic, Michael
    Carter, Adrian
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 109
  • [6] Prescription Drug Monitoring Programs Combating prescription drug misuse
    Gudoski, Anthony J.
    NURSE PRACTITIONER, 2015, 40 (11): : 28 - 33
  • [7] Provider-patient communication about prescription drug abuse: A qualitative analysis of the perspective of prescribers
    Mathis, Stephanie M.
    Hagaman, Angela
    Hagemeier, Nicholas
    Baker, Katie
    Pack, Robert P.
    SUBSTANCE ABUSE, 2020, 41 (01) : 121 - 131
  • [8] Prescription Drug Monitoring Programs and Drug Overdoses
    不详
    PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 304 - 304
  • [10] The evolution of prescription drug monitoring programs
    Ashburn, Michael A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (07) : 852 - 853